EVOK News and Press, Evoke Pharma Inc. From 02/09/24

2024-02-09 07:48:15 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma Read the full article on Seeking Alpha For further details see: Evoke ...

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that i...

--News Direct-- Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI in the U.S. Food and Drug Administration's publication, commonly known as t...

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its recently...

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that the United States Pat...

2023-11-10 08:55:21 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma For further details see: Evoke Pharma files to sell common stock and warrants

2023-11-09 09:00:42 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma For further details see: Evoke Pharma GAAP EPS of -$0.51, revenue of $1.56M

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide i...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Evoke Pharma Inc. (EVOK) is expected to report for Q1 2024